{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-103731","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2024-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.728517+00:00","generated_at":"2026-05-31T06:20:31.590984+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA grants Fast Track Designation for Perspective's VMT01 in MC1R-positive melanoma","bullets":["Fast Track for 212Pb VMT01: diagnosis and treatment of unresectable or metastatic MC1R-positive melanoma.","Designation enables more frequent FDA interactions and eligibility for accelerated/priority/rolling review.","Phase 1/2a Cohort 2 DLT observation period completed; safety data to be shared with SMC and scientific forum.","Company plans to open VMT01/anti-PD-1 combination cohort pending IRB approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-103731","json":"https://secwatch.observer/filing/0000950170-24-103731.json","markdown":"https://secwatch.observer/filing/0000950170-24-103731.md","text":"https://secwatch.observer/filing/0000950170-24-103731.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017024103731/0000950170-24-103731-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017024103731/catx-20240905.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:20:31.590984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}